CSP
1 min read
11

FISKARS CORPORATION: ACQUISITION OF OWN SHARES 03.12.2024

December 3, 2024
0

Reading Time: < 1 minute Stock Exchange Release 03.12.2024 at 18:30 EET/EEST   FISKARS CORPORATION: ACQUISITION OF OWN SHARES 03.12.2024   Date 03.12.2024   Exchange transaction Buy   Share class FSKRS   Amount  2,000   Average price/share 14.6426 EUR Highest price/share 14.6600 EUR Lowest price/share

Continue Reading
CSP
5 min read
14

Correction: Form 8.3 – Direct Line Insurance Group Plc

December 3, 2024
0

Reading Time: 4 minutes PLEASE SEE AMENDED CLASS OF RELEVANT SECURITY     FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)   1. KEY INFORMATION  

Continue Reading
Sweden 2025 – A Year Of Exciting Travel News Ahead
CSP
6 min read
14

Sweden 2025 – A Year Of Exciting Travel News Ahead

December 3, 2024
0

Reading Time: 4 minutes   The new Landskona Cold Bathing House. Photo: magazinA Architects to download.  With Sweden continuing to capture the imagination of travelers worldwide, 2025 promises an array of new openings, events, and experiences. From innovative hotels and inspiring cultural attractions to exciting

Continue Reading
CSP
5 min read
29

Biosergen AB receives approximately SEK 44.9 million through warrants of series TO3

December 3, 2024
0

Reading Time: 4 minutes Biosergen AB (”Biosergen” or the “Company”) announces today the outcome of the exercise of warrants of series TO3, which were issued in connection with a rights issue in the Company during the first quarter 2024. In total, 91,701,328 warrants of series TO3

Continue Reading
CSP
6 min read
11

Biosergen AB conducts a directed share issue to underwriters in connection with the completed exercise period for warrants of series TO3

December 3, 2024
0

Reading Time: 4 minutes The exercise period for Biosergen AB (”Biosergen” or the “Company”) warrants of series TO3 (the “Warrants”) was completed on November 29, 2024. In accordance with the underwriting agreements entered into in connection with the exercise of the Warrants, the Board of Directors

Continue Reading
CSP
1 min read
8

#24-415 Listing of Derivatives at NGM

December 3, 2024
0

Reading Time: < 1 minute Information about various derivatives that will be listed at NGM. For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGM Nordic Growth Market

Continue Reading
CSP
1 min read
7

#24-416 Delisting of Derivatives from NGM

December 3, 2024
0

Reading Time: < 1 minute Information about certain derivatives that will be delisted from NGM. For more details, see attached files. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGM Nordic Growth Market

Continue Reading
CSP
5 min read
7

Correction: Warrants of series TO5 were subscribed to approximately 87.1 percent and Wyld Networks AB receives approximately SEK 234 thousand

December 3, 2024
0

Reading Time: 4 minutes NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF

Continue Reading
CSP
1 min read
10

Notification under Chapter 9, Section 10 of the Finnish Securities Market Act

December 3, 2024
0

Reading Time: < 1 minute Neste Corporation, Stock Exchange Release, 3 December 2024 at 6 p.m. (EET) Neste Corporation has today received a notification under Chapter 9, Section 10 of the Finnish Securities Market Act (FSMA). According to the notification by BlackRock, Inc., the aggregate holdings of the entities referred

Continue Reading
Annual Report 2023/2024 – Diamyd Medical AB
CSP
1 min read
10

Annual Report 2023/2024 – Diamyd Medical AB

December 3, 2024
0

Reading Time: < 1 minute Diamyd Medical’s Annual Report for the financial year 2023/2024 is now available in English. The Annual Report is attached as a PDF and is available at www.diamyd.com. For further information, please contactUlf Hannelius, CEO, phone +46

Continue Reading